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1. Introduction
Fidaxomicin (1) is the first member of a class of antibiotics 
possessing an 18-membered, highly unsaturated macrolactone. [1] 
Fidaxomicin was first isolated in 1972 as lipiarmycin A3 by 
Gruppo Lepetit scientists from an actinobacterium along with 
similar natural products.[2] Interestingly, further bacterial strains 
were later found to produce similar compounds which were 
named clostomicins and tiacumicins, respectively.[3] Extensive 
structural studies revealed that lipiarmycin A3, clostomicin B1, 
and tiacumicin B are identical.[3a,4] Moreover, these studies iden-
tified the rhamnoside-dichlorohomoorsellinate moiety as well as 
the modified noviose as important structural features (Fig. 1).[5] 
Notably, the stereogenic center at C(18) was under discussion for 
a long time and it was assumed that lipiarmycin A3 and tiacumicin 
B distinguished themselves by the configuration of the C(18)-
stereocenter.[6] However, total synthesis campaigns,[7] extensive 
NMR analysis, and finally an X-ray analysis of these two natural 
products unambiguously verified their co-identity and revealed 
the (R)-configuration.[4]
Fidaxomicin (1) was reported to be active mainly against 
Gram-positive bacteria including strains not susceptible to 
other antibiotics. Excellent activities were reported against 
Clostridium difficile (recently reclassified as Clostridioides dif-
ficile)[8] and Clostridium perfringens as well as resistant strains 
of Staphylococcus aureus and Mycobacterium tuberculosis.[3a,f,9] 
No cross-resistance was observed with a broad panel of anti-
biotics. [2b,10] Although possessing activity against a variety of 
different bacterial strains, the clinical use of fidaxomicin (1) is 
currently limited to the treatment of C. difficile infections (CDI). 
The FDA approved the antibiotic 1 in 2011 for the treatment of 
hospital-acquired diarrhea caused by C. difficile and it was intro-
duced to the market as Dificlir®. Due to its low water solubility 
and thus low systemic absorption, treatment of infections outside 
the gut is not yet feasible.[11]
Tuberculosis (TB) remains one of the top ten causes of death 
worldwide. The WHO estimated that around 10 million people 
were infected in 2018 and around 1.5 million people died as 
a consequence.[12] Unfortunately, resistance is developing fast 
and spreads globally. In this context, fidaxomicin’s potential to 
become a useful antibiotic for the treatment of severe infections 
outside the gut has not yet been exploited. Despite its unfavor-
able bioavailability, this natural product could be a promising 
starting point in the development of new antibiotics. In 2012, 
Zhu and coworkers excellently reviewed the early history of fi-
daxomicin from its discovery to the introduction to the market 
in 2011,[1a] and a recent review article highlighted the synthetic 
aspects.[7g] This article focuses on the more recent advances in 
the field with emphasis on new insights into the biosynthesis 
and mechanistic aspects from cryo-EM structures and includes a 
summary of the antibacterial activities of the known derivatives. 


































































Fig. 1. Structure of the natural product fidaxomicin (1).
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3. Biosynthesis
In 2011, Zhang and coworkers reported a first proposal for 
the biosynthetic pathway of fidaxomicin based on a genetic 
approach. [17] Using gene-knockout mutants, Zhang and cowork-
ers isolated a great number of truncated fidaxomicin analogs 
which provided not only important information on involved en-
zymes and their functions, but also enabled a broad structure-ac-
tivity relationship (SAR) study. They identified the biosynthetic 
gene cluster of D. aurantiacum subsp. hamdenensis, one of the 
known producer strains. Sequence analysis and extensive analysis 
of truncated products obtained from the fermentation of gene-
knockout mutants led to the proposal of a reasonable biosynthesis, 
which was refined in following years.[18] Four genes (tiaA1-A4) 
were found to encode for a modular type I polyketide synthase 
(PKS) that generates the aglycon 2 starting from malonyl-CoA 
and derivatives thereof (Scheme 2). Next, the C(20)-position is 
oxidized by a cytochrome P450 (TiaP2) followed by noviosyl-
ation of OH-C(11) catalyzed by glycosyltransferase TiaG1 to 
give monoglycosylated 4. Subsequently, the rhamnosylation is 
mediated by glycosyltransferase TiaG2 and acyltransferase TiaS6 
installs the isobutyric ester moiety on the OH-C(4’’) on the novi-
ose. However, the catalytic order of TiaS6 and TiaG2 is not yet 
determined. Next, the homoorsellinic acid moiety 8, which is bio-
synthesized by a type I PKS from a propionyl-CoA starter unit 
and three malonyl-CoA extender units, is coupled to rhamnose 
OH-C(4’) by acyltransferase TiaF. The halogenase TiaM installs 
the chlorine substituents to the aryl 6 and methylation at OH-C(2’) 
occurs, however, the reaction timing remains elusive. As the last 
step in the biosynthesis, the oxidation in C(18)-position by TiaP1 
was ascertained via extensive kinetic studies.[18c]
4. Structure–Activity Relationship Studies
Structure–activity relationship (SAR) studies are of great im-
portance when considering the generation of new fidaxomicin an-
alogs with improved pharmacokinetic properties. Fig. 2 summa-
rizes all isolated, naturally occurring fidaxomicin analogs[2,3,5,19] 
as well as derivatives obtained by fermentation of gene-knockout 
mutants which produced truncated fidaxomicin analogs missing 
the noviose and/or the rhamnose moieties.[17,18] Semisynthetically 
synthesized analogs are listed, but their biological activity is omit-
ted due to lack of comparable biological data.[15b,20] Antibacterial 
activity has not been reported for all compounds and the exist-
ing data is difficult to compare due to the utilization of different 
assays and/or bacterial strains. Nevertheless, a general trend is 
observable. Accordingly, the noviose and rhamnose sugar moi-
ety are crucial for the antibacterial activity of 1. Analogs missing 
one or both of these moieties completely lose their antibacterial 
2. Mode of Action
The first report on the mode of action of fidaxomicin (1) ap-
peared soon after its discovery. Therein, Parenti and coworkers 
reported that antibiotic 1 interferes with RNA synthesis by in-
hibiting bacterial RNA polymerase (RNAP).[13] In the following 
decades, further progress in elucidation of the molecular basis 
of RNAP inhibition was achieved.[14] Recently, cryo-electron mi-
croscopy (cryo-EM) structures of fidaxomicin binding to M. tu-
berculosis RNAP, independently disclosed by the research groups 
of Campbell and Ebright, respectively, revealed the actual mecha-
nism of action.[15] The bacterial RNAP core enzyme consists of 
five subunits (ααββ’ω) and an initiation factor σ (Scheme 1).
Upon binding of the σ-factor, the so-called holoenzyme is 
formed.[16] During initiation of the transcription, the σ-factor 
recognizes the −35 and −10 promoter sequences of the DNA by 
undergoing a conformational change from an open to a closed 
clamp state. Next, the double-stranded DNA is melted to form an 
open promoter complex (RP
O
) onto which nucleotides can adhere 
to build up a new RNA strand. The cryo-EM structure revealed 
that fidaxomicin undergoes interactions with the β, β’ as well as 
σ-subunits at the switch-region. The switch-region is located at 
the base of the RNA clamp and mediates conformational changes. 
By binding to this region, fidaxomicin traps an open clamp state, 
thereby preventing simultaneous recognition of the −10 and −35 















Scheme 1. Mode of action of RNA polymerase inhibition by fidaxomicin (1).
Scheme 2. Proposed biosynthetic pathway of fidaxomicin (1).
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Fig. 2. Known fidaxomicin derivatives and their antibacterial activities given as minimum inhibitory concentrations (MIC, µg/mL).
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properties except for denoviosylated 9 and 10, which maintain 
some antibacterial activity even though significantly decreased 
compared to the parent compound 1. Noteworthy, a propyl (ana-
log 31) instead of an ethyl (analog 6) or methyl group (analog 30) 
on the homoorsellinic acid with lacking chloride substituents is 
beneficial for the antibacterial activity.
Moreover, the isobutyric ester moiety on the noviose is crucial 
for its excellent activity. Hydrolysis of this isobutyric ester (61, 
OP-1118, known metabolite of fidaxomicin) leads to a more than 
8-fold decrease in activity against C. difficile.[21] Replacement 
of isobutyric ester by propionic ester (49) or acetate (53) also 
diminishes the activity. Migration of the isobutyric ester to the 
OH-C(2’’) (64) is not tolerated and results in 8–16-fold increase 
of the minimum inhibitory concentration (MIC) value, whereas 
OH-C(3’’) (65) largely retains activity. For the compounds lack-
ing the OH-C(18) group, the results are ambiguous. While fidax-
omicin without the OH-C(18) group (7) slightly loses activity, 
an analog lacking OH-C(18) as well as C(7’)-methyl group (41) 
shows improved activities. However, the compound only lacking 
C(7’)-methyl group (36) also shows  decreased activity. In con-
trast, the influence of the chloride substituents on the homoorsell-
inic acid moiety (6, 73, 75) only appears to have a small influence 
on the antibiotic activity of fidaxomicin (1). 
5. Conclusion and Outlook
With regard to the current precarious situation due the emer-
gence of antibiotic-resistant bacteria, new antibiotics are urgently 
needed. The synthesis of new fidaxomicin analogs with improved 
bioavailability might allow for the treatment of infections like tu-
berculosis. These recent insights into the biosynthesis as well as 
mechanistic processes enable the generation of new fidaxomicin 
antibiotics based on structural considerations. 
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